Anti-mu treatment suppresses immunoglobulin light-chain gene expression and Peyer's patch development.
Anti-mu treated mice have been used extensively as a model for suppressed B-cell development [Murgita R. A., Mattioli C. A. and Tomasi T. B., Jr. (1973) J. exp. Med. 138, 209; Manning D. D. (1975) J. Reticuloendothel. Soc. 18, 63; Manning D. D. and Jutila J. W. (1972) J. Immun. 108, 282; Janeway C. A., Jr., Murgita R. A., Weinbaum F. I., Asofsky R. and Wigzell H. (1977) Proc. natn. Acad. Sci. U.S.A. 74, 4582; Hayglass K. T., Naides S. J., Benacerraf B. and Sy M.-S. (1985) J. Molec. Cell. Immun. 2, 107; Manning D. D. (1972) J. Immun. 109, 1152; Cooper M. D., Kearney J. F., Gathings W. E. and Lawton A. R. (1980) Immun. Rev. 52, 29; Burrows P. D., Kearney J. F., Lawton A. R. and Cooper M. D. (1978) J. Immun. 120, 1526]. However, little molecular evaluation has been performed on these animals to determine the level at which B-lineage cells are arrested. Experiments reported here were designed to determine the effects of anti-mu treatment of newborn mice on Ig-specific mRNA expression in lymphocyte populations. Newborn CBA/J mice received i.p. injections of goat anti-mu IgG or non-immune goat IgG, every 2 days, from birth until age 4 weeks. The degree of B-cell suppression in anti-mu treated mice was evident by low serum Ig levels and lack of surface Ig+ cells in splenic lymphocytes. Morphologically, spleens of B-cell depleted mice were slightly reduced or normal size, while the total area of Peyer's patches (PP) was three-fold less than control mice. Spleen cells from anti-mu suppressed mice contained high levels of mu-mRNA, but markedly reduced levels of mRNA specific for other Ig heavy-chain isotypes, as determined by DNA excess dot blot and Northern blot hybridizations. RNA specific for other sequences (actin or IL-2 receptor) was not affected and hybridization to parent plasmid (pACYC) was not detected. In addition, suppression of kappa- and lambda-mRNA accumulation was evident. This was surprising, since the target for anti-mu treatment appears to be a B-cell population expressing intact surface IgM, a stage in B-cell development in which both mu- and light-chain-specific mRNA accumulation should be detected. Our results suggest one of the following models: (1) anti-mu treatment deletes all Ig+ cells from the animal, so that only mu expressing pre-B-cells remain; or (2) anti-mu suppresses B-cell development by inhibiting kappa and lambda transcription, perhaps by some feedback mechanism in which the presence of surface Ig is required to maintain light-chain transcription.
Woloschak
G E
GE
Department of Immunology, Mayo Clinic, Rochester, MN 55905.
Krco
C J
CJ
Rodriguez
M
M
D000818:Animals; D001402:B-Lymphocytes / Q000276:immunology; D015152:Blotting, Northern; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005796:Genes; D007147:Immunoglobulin Light Chains / Q000235:genetics* / Q000276:immunology; D007136:Immunoglobulins / Q000276:immunology*; D051379:Mice; D008808:Mice, Inbred CBA; D010581:Peyer's Patches / Q000473:pathology*; D012333:RNA, Messenger / Q000235:genetics
D007147:Immunoglobulin Light Chains; D007136:Immunoglobulins; D012333:RNA, Messenger